Clinical Trial Update: A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma [Phase 2]

View source ↗

Summary

Phase 2b trial evaluating a combination immunotherapy for newly diagnosed glioblastoma is currently active but not recruiting. Sponsor is Imvax.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Imvax combination immunotherapy

Snippet

Sponsor: Imvax | Conditions: Glioblastoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING